Targets › MMUT
1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Apr 2034.
Catalyzes the reversible isomerization of methylmalonyl-CoA (MMCoA) (generated from branched-chain amino acid metabolism and degradation of dietary odd chain fatty acids and cholesterol) to succinyl-CoA (3-carboxypropionyl-CoA), a key intermediate of the tricarboxylic acid cycle. (UniProt, P22033)
Open in Phaseline: the race on MMUT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| ModernaTX | mRNA-3705 modified mRNA encoding human methylmalonyl-coenzyme A mutase (MUT) | MMUT | Phase 1 | Methylmalonic Acidemia | Apr 2034 |
Methylmalonic Acidemia (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.